AB Science
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
AB | PA
Overview
Corporate Details
- ISIN(s):
- FR0010557264 (+1 more)
- LEI:
- 969500U43TVR8CCVBJ97
- Country:
- France
- Address:
- 3 AVENUE GEORGE V, 75008 PARIS
- Website:
- https://www.ab-science.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
AB Science, founded in 2001, is a clinical-stage pharmaceutical company specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs). The company focuses on developing targeted therapies for diseases with high unmet medical needs. Its pipeline is centered on two lead compounds, masitinib and AB8939, which are being investigated for use in oncology (e.g., Acute Myeloid Leukemia), neurodegenerative disorders (e.g., ALS, Alzheimer's, Multiple Sclerosis), and inflammatory diseases. AB Science also commercializes Masivet®, a tyrosine kinase inhibitor for use in veterinary medicine.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-30 18:32 |
Report Publication Announcement
AB Science annonce annonce un léger décalage de la publication de son rapport f…
|
French | 165.7 KB | ||
| 2025-09-30 18:32 |
Report Publication Announcement
AB Science announces a slight delay in the publication of its 2025 half-year fi…
|
English | 192.5 KB | ||
| 2025-08-04 07:58 |
Share Issue/Capital Change
AB Science annonce le succès d’un placement privé d’environ 2,55 millions d’eur…
|
French | 332.3 KB | ||
| 2025-08-04 07:58 |
Share Issue/Capital Change
AB Science announces the successful completion of a 2.55 million euros private …
|
English | 323.2 KB | ||
| 2025-07-24 07:56 |
Regulatory News Service
AB Science has received approval from several European countries to initiate th…
|
English | 297.9 KB | ||
| 2025-07-24 07:56 |
Legal Proceedings Report
AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’é…
|
French | 273.3 KB | ||
| 2025-06-23 08:03 |
Regulatory News Service
AB Science - New peer-reviewed data provide strong evidence supporting masitini…
|
English | 307.5 KB | ||
| 2025-06-23 08:03 |
Regulatory News Service
AB Science - De nouvelles données évaluées par des pairs apportent des preuves …
|
French | 290.6 KB | ||
| 2025-06-12 07:59 |
Legal Proceedings Report
AB Science annonce la délivrance d’un brevet canadien protégeant la composition…
|
French | 197.9 KB | ||
| 2025-06-12 07:59 |
Regulatory News Service
AB Science announces issuance of a Canadian patent protecting the composition o…
|
English | 221.7 KB | ||
| 2025-06-09 08:00 |
Regulatory News Service
AB Science annonce l’approbation par l’EMA de la prolongation de la durée de co…
|
French | 164.5 KB | ||
| 2025-06-09 08:00 |
Report Publication Announcement
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
|
English | 194.6 KB | ||
| 2025-05-23 07:52 |
Share Issue/Capital Change
AB Science announces the settlement delivery of its latest capital increase for…
|
English | 199.0 KB | ||
| 2025-05-23 07:52 |
Share Issue/Capital Change
AB Science :
|
French | 229.0 KB | ||
| 2025-05-20 07:49 |
Share Issue/Capital Change
AB Science annonce le succès d'un placement privé de 1,8 millions d'euros
|
French | 282.8 KB |
Automate Your Workflow. Get a real-time feed of all AB Science filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AB Science
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AB Science via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
